{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-22-000011","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2022-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.228715+00:00","generated_at":"2026-06-26T03:48:40.490026+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AptarGroup Q1 revenue up 9% to $845M; adjusted EPS down to $0.96 from $1.05","bullets":["Reported sales $845M (+9% YoY); core sales +13% with double-digit growth in all segments.","Adjusted EPS $0.96 vs $1.05 prior year; reported EPS $0.93 included $0.19 unrealized gain in prior year.","Pharma core sales +13%; demand for allergic rhinitis and asthma devices recovering.","Q2 2022 adjusted EPS guidance $0.92-$1.02; midpoint +14% on constant-currency basis.","Dividend maintained at $0.38/share; $16M share repurchases in Q1, $184M remaining authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-22-000011","json":"https://secwatch.observer/filing/0000896622-22-000011.json","markdown":"https://secwatch.observer/filing/0000896622-22-000011.md","text":"https://secwatch.observer/filing/0000896622-22-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662222000011/0000896622-22-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662222000011/atr-20220428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T03:48:40.490026+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}